I-Mab ADR (NASDAQ:IMAB)’s traded shares stood at 0.37 million during the last session, with the company’s beta value hitting 1.04. At the close of trading, the stock’s price was $0.88, to imply a decrease of -2.22% or -$0.02 in intraday trading. The IMAB share’s 52-week high remains $2.54, putting it -188.64% down since that peak but still an impressive -2.27% since price per share fell to its 52-week low of $0.90. The company has a valuation of $67.78M, with an average of 0.63 million shares in intraday trading volume over the past 10 days and average of 447.33K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for I-Mab ADR (IMAB), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give IMAB a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.05.

I-Mab ADR (NASDAQ:IMAB) trade information

After registering a -2.22% downside in the last session, I-Mab ADR (IMAB) has traded red over the past five days. The 5-day price performance for the stock is -7.68%, and -7.07% over 30 days. With these gigs, the year-to-date price performance is -53.68%. Short interest in I-Mab ADR (NASDAQ:IMAB) saw shorts transact 0.59 million shares and set a 1.11 days time to cover.

I-Mab ADR (IMAB) estimates and forecasts

Looking at statistics comparing I-Mab ADR share performance against respective industry, we note that the company has outperformed competitors. I-Mab ADR (IMAB) shares are -47.31% down over the last 6 months, with its year-to-date growth rate higher than industry average at 67.61% against 16.60%. The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -18.89% for the past 5-year period. While 2024 is set for a 87.13% return in earnings, projections for the next 5 years are at 26.00% annually.

IMAB Dividends

I-Mab ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is CALIGAN PARTNERS LP with 3.37 million shares, or about 3.8067% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $5.64 million.

We also have abrdn Healthcare Investors and abrdn Healthcare Opportunities Fund as the top two Mutual Funds with the largest holdings of the I-Mab ADR (IMAB) shares. Going by data provided on Sep 30, 2024 , abrdn Healthcare Investors holds roughly 53.88 shares. This is just over 0.07% of the total shares, with a market valuation of $47418.0. Data from the same date shows that the other fund manager holds a little less at 43.74, or 0.05% of the shares, all valued at about 38489.0.